Ares Life Sciences, a healthcare-focused investment group, has signed a definitive agreement to acquire Planet Biopharmaceuticals, Inc., including its wholly owned subsidiary Antigen Laboratories, Inc., a producer of allergen extracts in the U.S. Financial terms were not disclosed. Ares also recently signed an agreement to acquire Greer Laboratories, Inc., another provider in the U.S. allergy immunotherapy (AIT) market. The acquisition of Antigen expands Ares’ strategic focus on the U.S. AIT market.

Jacques Theurillat, chief executive officer of Ares Life Sciences, said, “As an FDA licensed manufacturer, Antigen has one of the most comprehensive offerings of allergenic extracts in the United States and has a long track record of serving the needs for the ENT specialists. We view the acquisition of Antigen as very complementary to our other investments in the allergy market.”
 
Theron E. Odlaug, Planet Biopharmaceuticals executive chairman and chief executiveofficer, said, “We are looking forward to becoming a member of the Ares portfolio of life science companies and the resources they will provide to help us continue to grow.”